经肝动脉灌注~(32)磷-玻璃微球治疗不能切除的原发性肝癌

• 出 处: 中山医科大学学报
• 发表日期: 1998年S1期
• 关键词: 原发性肝癌 肝动脉灌注 肝动脉化疗栓塞 治疗应用 近距离放射疗法 内放射治疗 肝肿瘤 磷放射性同位素 药盒 肝动脉给药

目的：探讨３２磷玻璃微球（３２ＰＧＭＳ）治疗手术不能切除的原发性肝癌的效果。方法：用３２ＰＧＭＳ通过皮１下埋藏药盒注入肝动脉，选择性内放射治疗（ＳＩＲＴ）８例经手术证实不可切除的原发性肝癌，３２ＰＧＭＳ用量为０．６～１．８ＧＢｑ。并与同期的２０例肝动脉化疗栓塞（ＨＡＣＥ）治疗病例比较。结果：ＳＩＲＴ组无治疗死亡，治疗后３、６、１０个月生存率分别为１００％、６３．５％、３２．８％，中位生存期１０．３个月；ＡＦＰ有不同程度下降，幅度８７．５％～９９．８％，Ｂ型超声、电子计算机体层扫描显示肿瘤体积平均缩小３１．０％（２１．０％～６３．５％），有效率７５．０％，明显优于ＨＡＣＥ。结论：经肝动脉灌注３２ＰＧＭＳ治疗手术不能切除的原发性肝癌，兼有栓塞和放射治疗的双重优点，临床使用安全、方便，疗效较肝动脉化疗栓塞为优

Objective: To investigate the effect of 32PGMS microspheres (32PGMS) in the treatment of unresectable primary liver cancer. Methods: 32PGMS was used to inject the hepatic artery into the hepatic artery through a subcutaneous burial kit. Selective internal radiotherapy (SIRT) was performed in 8 patients with unresectable primary liver cancer confirmed by surgery. The dose of 32PGMS was 0.6–1.8 GBq. . And compared with the same period of 20 cases of hepatic arterial chemoembolization (HACE) treatment. Results: There was no treatment death in the SIRT group. The survival rates at 3, 6 and 10 months after treatment were 100%, 63.5%, and 32.8%, respectively. The median survival time was 10.3 months. AFP decreased in different degrees. The amplitude ranged from 87.5% to 99.8%. B-mode ultrasound and computed tomography showed that the tumor volume decreased by 31.0% (21.0%-63.5%) on average, and the effective rate was 75.0%. On HACE. Conclusion: Hepatic artery perfusion 32P  GMS treatment of primary hepatocellular carcinoma can not be removed, both the advantages of embolization and radiation therapy, clinical use of safe and convenient, the effect is better than hepatic arterial chemoembolization